A carregar...
A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer
BACKGROUND: The clinical challenges of triple-negative breast cancer (TNBC) includes the lack of targeted therapy and chemoresistance. TNBC has relatively high PD-L1 expression, and PD-L1 antibody in combination with nab-paclitaxel has been approved by FDA for TNBC treatment. Aptamers, also termed c...
Na minha lista:
| Publicado no: | Med Sci Monit |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Scientific Literature, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7331476/ https://ncbi.nlm.nih.gov/pubmed/32574155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.925583 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|